One New Sector is Expected to Double Its Value in This Decade – And You Can Cover It All with Only One Investment

0 | By Michael A. Robinson

Despite the coronavirus panic – or perhaps because of it – the robotics industry recently saw deals worth $3 billion.

Here’s the thing. We’re just scratching the surface here.

That amount only covers high-profile deals by two major Silicon Valley firms. One was for venture capital funding and the other for a big merger.

But quietly and behind the scenes, robotics and automation firms garnered at least another $3.9 billion in funding.

And that’s just for February and March of this year.

So, it should come as no surprise that with the coronavirus serving as a fresh catalyst, robotics adoption is likely to grow significantly from here.

After all, one of the most significant effects of the coronavirus has been the fact that it has driven businesses to get human hands off of important work, whether that’s through digital connections or robotic automation.

A new report by MarketsandMarkets says that just the use of industrial bots will grow by roughly 10.4% year, meaning it will double by the end of this decade to more than $73 billion.

With that in mind, today I want to reveal a great way to play the broad waterfront of this field with a market-crushing investment…

Five Reasons Why This Pharmaceutical Specialist Could Double Your Money in Just Two Years

0 | By Michael A. Robinson

In our twice-weekly chats, I often suggest investments that are part of large tech sectors.

For instance, the life sciences field defines huge. Just the prescription drug segment alone will be worth $1.2 trillion by 2024, according to data from Statista.

So, you might be wondering why I am focused on a medical area that will be worth just 0.1% of that figure over roughly the same time frame.

It’s a fair question. The answer is pretty basic. A high-octane leader
focused on specialty drugs can make a killing.

And the one I’m going to reveal to you today defines profit machine. It’s on pace to double per-share earnings in as little as a year.

With that in mind, let me show you five reasons why this wealth-building biotech firm should at the very least be on your radar screen….

Recent Articles